– Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p<0.0001) – – 87.1% of Patients Treated with Combination of Obicetrapib and...
Data update from AFM24-101 phase 1/2 monotherapy study includes 15 patients from the EGFR mutant non-small cell lung cancer (NSCLC)...
Long Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19 CAR T to Generate Durable...
Early on-treatment ctDNA reduction in stable disease patients treated with KIMMTRAK was associated with longer overall survival (OXFORDSHIRE, England &...
CALGARY, Alberta, June 02, 2023 (GLOBE NEWSWIRE) -- Providence Therapeutics Holdings Inc. ("Providence"), a biopharmaceutical company developing messenger RNA (mRNA)...
HINGHAM, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic Surgical...
Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of...
PURCHASE, N.Y., June 02, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), announced today that...
Carlsbad, CA, June 01, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies...
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (or the “Company”) (NASDAQ: AMAM), today announced...
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its...
SAB Biotherapeutics President & Chief Executive Officer Eddie Sullivan, Ph.D. to present novel DiversitAb™ platform pipeline, with emphasis on partnering...
SINGAPORE and BETHESDA, Md., May 30, 2023 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a global clinical-stage biotechnology company...
New data show continued durability of response over 14 months with humoral immune responses increasing over time LAWRENCEVILLE, N.J., May...
Total revenue of $15.1 million in Q1 2023 represents a 24% sequential increase over Q4 2022.Net Revenue in medical accounted...
With the Glitz and Glamour of a 20s Speakeasy, the Gala Honoured the Achievements of Dr. Kevin Schwartzman and the...
INSIDE INFORMATION Maintenance of the license is now subject to the launch of the OATO Phase III before May 2024...
Priority Review Granted withPrescription Drug User Fee Act (PDUFA) Action Date of November 25, 2023 First Potential Approval of an...
ROCKAWAY, N.J., May 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced...
NEW YORK, May 26, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical...